Remarkable Technologies, Inc., of Farmington, CT, has announced the first license of its patented treatment approach for Alzheimer’s Disease.
The company’s U.S. patent 9,037,268 issued on May 19th for “Skull-focused RF-based stimulation apparatus, system and method for treating patients with Alzheimer’s disease or other dementia” was licensed by NeuroEM Therapeutics, Inc. of Phoenix, AZ.
NeuroEM is headed up by Dr. Gary Arendash, widely recognized as the world leader in RF-based research for the treatment of Alzheimer’s Disease. Dr. Arendash is also the Senior Editor of the Journal of Alzheimer’s Disease.
Eric Knight, Founder and President of Remarkable Technologies commented, “We are abundantly proud to be teaming up with Dr. Arendash and his company. It’s the first of what we hope to be many patent licenses in our multi-faceted effort to tackle this terrible disease.”